Empiric investigation on direct costs-of-illness and healthcare utilization of medicaid patients with diabetes mellitus

American Journal of Managed Care

Volumn 4, Issue 10, 1998, Pages 1433-1446

  Guo, Jeff Jianfei ^a   Gibson, J Tyrone ^b   Gropper, Daniel M ^c   Oswald, Sharon L ^c   Barker, Kenneth N ^c  

^a UNITED STATES PHARMACOPEIA   (United States)

^b Health Data Inc   (United States)

^c AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMORBIDITY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LABORATORY; MEDICAID; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DEMOGRAPHY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH SERVICES; HUMANS; MALE; MEDICAID; MIDDLE AGED; UNITED STATES;

EID: 0031790895     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. American Diabetes Association. Diabetes 1996 Vital Statistics. Alexandria, VA: American Diabetes Association; 1996:1-20.
2. Dorman JS, McCarthy BJ, O'Leary LA, Koehler AN. Risk factors for insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MP, et al, eds. Diabetes in America. Bethesda, MD: National Institute of Health, National Institutes of Diabetes and Digestive and Kidney Diseases; 1995:165-178. NIH publication no. 95-1468.
3. Rewers M, Hamman RG. Risk factors for non-insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MP, et al, eds. Diabetes in America. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:179-220. NIH publication no. 95-1468.
4. American Medical Association. "Agents used to regulate blood glucose". AMA Drug Evaluations Annual 1995. Chicago: American Medical Association; 1995:1063-1091.
5. Diabetes Source Book. Washington, DC: US Dept of Health, Education, and Welfare; 1968:7. PHS publication no. 1168.
6. American Diabetes Association. Direct and Indirect Costs of Diabetes in the United States in 1992. Alexandria, VA: American Diabetes Association; 1993:1-27.
7. Rice DP. Estimating the Costs of Illness. Health Economics Series. Washington, DC: Government Printing Office; 1966. PHS publication no. 947-6.
8. Leese B. Diabetes mellitus and the St. Vincent declaration: The economic implications. PharmacoEconomics 1995;7:292-307.
9. Pracon Incorporated Center for Economic Studies of Medicine. Direct and Indirect Costs of Diabetes in the United States in 1987. Alexandria, VA: American Diabetes Association; 1988.
10. Harris MI. Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus. National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Disease. Clin Invest Med 1995;18:231-239.
11. Jacobs J, Sena M, Fox N. The cost of hospitalization for the late complications of diabetes in the United States. Diabet Med 1991;8(suppl):S23-S29.
12. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of non-insulin-dependent diabetes mellitus. JAMA 1989;262:2708-2713.
13. Center for Disease Control. Economic cost of diabetes mellitus - Minnesota, 1988. MMWR 1991;40:229-231.
14. Oklahoma State Department of Health. Diabetes mellitus - its economic impact. J Okla State Med Assoc 1991;84:30-31.
15. Olsson J, Persson U, Tollin C, et al. Comparison of excess costs of care and production losses because of morbidity in diabetic patients. Diabetes Care 1994;17: 1257-1263.
16. Bruce DG, Clark EM, Danesi GA, et al. Outpatient initiation of insulin therapy in patients with diabetes mellitus. Med J Australia 1987;146:19-22.
17. McKendry JBR. Direct costs of diabetes care: A survey in Ottawa, Ontario, 1986. Can J Public Health 1989;80: 124-129.
18. Gagliardino JJ, Olivera EM, Barragan H, et al. A simple economic evaluation model for selecting diabetes healthcare strategies. Diabetes Medica 1993;10:351-354.
19. Triomphe A, Flori YA, Costagliola D, et al. The cost of diabetes in France. Health Policy 1988;9:34-48.
20. Guo JJ, Gibson JT, Barker KN. Costs of prescription drugs for diabetes mellitus Medicaid patients in Alabama: A population-based study. Clin Ther 1996;18(suppl A):51. Abstract.
21. Maryland Department of Health and Mental Hygiene. Identifying a Population at Risk: Diabetes within the Maryland Medicaid Population. Medicaid Management Short Reports. Baltimore, MD: Department of Health and Mental Hygiene; 1990.
22. Wertheimer AI, Curtiss FR. Healthcare institutions and the healthcare system. In: Brown TR, ed. Handbook of Institutional Pharmacy Practice. American Society of Hospital Pharmacists; Bethesda, MD 1992:5.
23. Phelps CE. "Other government health care programs". Health Economics. New York: Harper Collins Publishers; 1992:363-380.
24. Moore WJ, Newman RJ. US Medicaid drug formularies: Do they work? PharmacoEconomics 1992;1(suppl):28-31.
25. Holmes A. Medicaid drug utilization review aims to cut costs, but fights an uphill battle for acceptance. In: Drug Outcomes Sourcebook. Washington, DC: Faulkner & Gray's Inc; 1995:414-416.
26. Iglehart JK. Health policy report. The American healthcare system: Medicaid. N Engl J Med 1993;328:896-900.
27. Levit KR, Lazenby HC, Cowan CA, et al. State health expenditure accounts: Building blocks for state health spending analysis. Health Care Financ Rev 1995;17: 201-254.
28. Krans HMJ. Foreword of the social and cost implications of Type II diabetes. PharmacoEconomics 1995;8(suppl 1):1.
29. Zitter M. Disease management: A systems approach to managing health outcomes. Med Interface 1995;1:70-90.
30. Leese B. The costs of diabetes and its complications. Soc Sci Med 1992;10:130-140.
31. Simell TT, Sintonen H, Hahl J, Simell OG. Costs of insulin-dependent diabetes mellitus. PharmacoEconomics 1996;9:24-38.
32. Songer TJ. The economic costs of NIDDM. Diabetes Metab Rev 1992;8:389-404.
33. Leese B. Economic evaluations of type II diabetes. PharmacoEconomics 1995;8(suppl):23-27.
34. Feldstein PJ. The demand for medical care. In: Health Care Economics. New York: John Wiley & Sons Inc; 1979:79-81.
35. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 1996;125:221-232.
36. Carter Center of Emory University. Closing the gap: The problem of diabetes mellitus in the United States. Diabetes Care 1985;8:391-406.
37. Johnson JA, Bootman JL. Drug-related morbidity and mortality: Costs-of-illness model. Arch Intern Med 1995; 155:1949-1956.
38. Glauber HS, Brown JB. Use of health maintenance organization database to study pharmacy resource usage in diabetes mellitus. Diabetes Care 1992;15:870-876.
39. Law AV, Pathak DS, Segraves AM, Weinstein CR, Arneson WH. Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic. Clin Ther 1995;17:977-987.
40. Nichol MB, Margolies JE. Retrospective cost comparison of second generation diabetic agents. Program for American Pharmaceutical Association Annual Meeting 1995;142(Mar): 129. Abstract.
41. Sclar DA, Skaer TL. Effect of medication utilization review on Medicaid healthcare expenditures: A case study of patients with non-insulin-dependent diabetes mellitus. J Res Pharm Econ 1991;3:75-89.
42. Simell T, Simell O, Sintonen H. The first two years of type 1 diabetes in children: Length of the initial hospital stay affects costs but not effectiveness of care. Diabetic Med 1993;10:855-862.
43. Miller LV, Goldstein BA. More efficient care of diabetic patients in a county hospital setting. N Engl J Med 1972; 286:1388-1391.
44. Bureau of Labor Statistics. Summary data from the producer price index: 1993-1995. Washington, DC: US Department of Labor; 1993, 1994, 1995.
45. Dept of Health and Human Services. St. Anthony's ICD-9-CM Code Book for Physician Payment. Alexandria, VA: St. Anthony Publishing Inc; 1994.
46. Greene WH. Lectke J, ed. "Systems of regression equations." In: Econometric Analysis. New York: Macmillan Publishing Company; 1993:53-76, 140-170.
47. Hair JF, Anderson RE, Tatham RL, Black WC. Canonical correlation analysis. In: Easter F, ed. Multivariate Data Analysis with Readings. New York: Macmillan Publishing Company; 1992:1-10, 193-264.
48. American Diabetes Association. Clinical practice recommendations. Screening for diabetes: Position statement. Diabetes Care 1991;14:7-9.
49. Miller LV, Goldstein J, Kumar D, Dye L. Assessment of program effectiveness at the Los Angeles County-University of Southern California Medical Center. In: Steiner G, Lawrence PA, eds. Educating Diabetic Patients. New York: Springer Publishing Company; 1981:349-359.
50. Assal JP. Cost-effectiveness of diabetes education. PharmacoEconomics 1995;8(suppl 1):68-71.
51. Bartlett EE. Cost-benefit analysis of patient education. J Patient Edu Counsel 1995;26:87-91.
52. Davidson JK. The Grady Memorial Hospital diabetes unit ambulatory care program. In: Assal J-Ph, et al, eds. Diabetes Education: How to Improve Patient Education. Amsterdam: Excerpta Medica; 1983:286-297.
53. Neresian W. Impact of diabetes outpatient education - Maine. MMWR 1982;31:307-313.
54. Guo JJ. A Pharmacoeconomic Study of Diabetes Mellitus Medicaid Patients: A Theoretical Model and Empirical Investigation [dissertation]. Auburn, AL: Auburn University; March 1997.